Earnings ·
Reports Q3 net loss of $25.8M, $0.20 per share; cash balance stands at $187.7 million
ZURAZura Bio Ltd
Zura Bio Limited reported a third-quarter 2026 net loss of $25.8 million, or $0.20 per share, compared to a loss of $18.0 million, or $0.21 per share, in the same period last year. Research and development expenses increased to $19.5 million from $11.9 million, driven by clinical program execution and startup activities for the NEXUS-PMR study. General and administrative expenses rose to $9.3 million from $7.6 million due to higher professional fees. The company held cash and cash equivalents of $187.7 million as of September 30, 2026, which management expects will fund operations through at least the end of 2028. Zura Bio is a clinical-stage biotechnology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases.